CORONA REMEDIES Latest Share Price (CORONA)
TODAY IN ONE LINE
CORONA edged up 0.3%, outperforming Nifty's -1.1% move.
With a market cap of ₹12,312.75 Cr., it trades at a P/E of 61.87. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
CORONA REMEDIES flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Capital EfficiencyROCE of 20.9% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 24.3%
- ●Healthy Operating MarginsOPM is structurally strong at 15.9%
- ●High Promoter HoldingPromoters hold 69.0% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.19x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Expensive ValuationTrading at a high P/E ratio of 64.9x
Latest CORONA REMEDIES News
What changed recently?
Recent events, corporate actions, and announcements.
CORONA REMEDIES valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for CORONA REMEDIES, framed against the sector median so the premium or discount is obvious at a glance.
CORONA REMEDIES trades at a P/E of 61.87× and P/B of 16.49×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
CORONA REMEDIES technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for CORONA REMEDIES — derived from the latest tape, not yesterday's close.
CORONA REMEDIES last traded at ₹2,010 with an intraday range of ₹1,985.9–₹2,026 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹2010.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2108.90 | +98.90 | +4.92% |
| R3 | 2068.80 | +58.80 | +2.93% |
| R2 | 2047.40 | +37.40 | +1.86% |
| R1 | 2028.70 | +18.70 | +0.93% |
| PIVOT | 2007.30 | -2.70 | -0.13% |
| CURRENT | 2010.00 | — | — |
| S1 | 1988.60 | -21.40 | -1.06% |
| S2 | 1967.20 | -42.80 | -2.13% |
| S3 | 1948.50 | -61.50 | -3.06% |
| S4 | 1908.40 | -101.60 | -5.05% |
CORONA is trading Above CPR, indicating Bullishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹1985.9–₹2018.4
Trading Inside opening range
CORONA REMEDIES financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for CORONA REMEDIES — consolidated or standalone — with margins, YoY growth and key ratios inline.
CORONA REMEDIES reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹12,312.75 Cr. and reported EPS of ₹9.83.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 1,403 | 1,403 ▲ 0.0% |
| Other Income | 11 | 11 ▲ 0.0% |
| Total Income | 1,414 | 1,414 ▲ 0.0% |
| 261 | 261 ▲ 0.0% | |
| Gross ProfitDerived | 1,142 | 1,142 ▲ 0.0% |
| Gross Margin %Derived | 81.40% | 81.40% |
| 849 | 849 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 293 | 293 ▲ 0.0% |
| OPM %Derived | 20.91% | 20.91% |
| 26 | 26 ▲ 0.0% | |
| Profit Before Tax (PBT) | 240 | 240 ▲ 0.0% |
| 55 | 55 ▲ 0.0% | |
| Effective Tax %Derived | 23.00% | 23.00% |
| Total Profit for Period | 185 | 185 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | 185 | 185 ▲ 0.0% |
| Net Profit Margin %Derived | 13.19% | 13.19% |
| Earnings Per Share (EPS ₹) | 30.27 | 30.27 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 6 | 6 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 1,173 | 1,173 ▲ 0.0% |
| Material Cost % of RevenueDerived | 7.38% | 7.38% |
| Employee Cost % of RevenueDerived | 28.72% | 28.72% |
| Other Cost % of RevenueDerived | 31.77% | 31.77% |
| Interest Coverage (x)Derived | 36.67x | 36.67x |
| Period | Mar 2026 | May 2026 | Trend |
|---|---|---|---|
| Revenue from Operations | 1,403 | 1,403 ▲ 0.0% | |
| Other Income | 11 | 11 ▲ 0.0% | |
| Total Income | 1,414 | 1,414 ▲ 0.0% | |
261 | 261 ▲ 0.0% | ||
| Gross ProfitDerived | 1,142 | 1,142 ▲ 0.0% | |
| Gross Margin %Derived | 81.40% | 81.40% | |
849 | 849 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 293 | 293 ▲ 0.0% | |
| OPM %Derived | 20.91% | 20.91% | |
26 | 26 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 240 | 240 ▲ 0.0% | |
55 | 55 ▲ 0.0% | ||
| Effective Tax %Derived | 23.00% | 23.00% | |
| Total Profit for Period | 185 | 185 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 185 | 185 ▲ 0.0% | |
| Net Profit Margin %Derived | 13.19% | 13.19% | |
| Earnings Per Share (EPS ₹) | 30.27 | 30.27 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 6 | 6 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 1,173 | 1,173 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 7.38% | 7.38% | |
| Employee Cost % of RevenueDerived | 28.72% | 28.72% | |
| Other Cost % of RevenueDerived | 31.77% | 31.77% | |
| Interest Coverage (x)Derived | 36.67x | 36.67x |
CORONA REMEDIES segment analysis : revenue and profit mix.
Disclosed business segments at CORONA REMEDIES with their share of revenue and profit, switchable between consolidated and standalone reporting.
CORONA REMEDIES discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for CORONA REMEDIES.
Our AI distills the core fundamental drivers supporting CORONA REMEDIES, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Valuation risk. a P/E above 80 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 19% would indicate weaker capital compounding.
CORONA REMEDIES peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — CORONA REMEDIES is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
CORONA REMEDIES chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for CORONA REMEDIES — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
CORONA REMEDIES delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for CORONA REMEDIES over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in CORONA REMEDIES stood at 75.1% of traded volume, against a 20-day average of 55.2%.
CORONA REMEDIES announcements: results, concalls, ratings, M&A.
Filings CORONA REMEDIES sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
CORONA REMEDIES files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 76 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
CORONA Remedies Limited has informed the Exchange about Schedule of meet
Certificate under SEBI (Depositories and Participants) Regulations, 2018
CORONA Remedies Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Credit Rating
CORONA Remedies Limited has informed the Exchange about Credit Rating
Trading Window
CORONA Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,…
Analysts/Institutional Investor Meet/Con. Call Updates
CORONA Remedies Limited has informed the Exchange about Schedule of meet
Investor decks & rating reports.
CORONA REMEDIES dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue CORONA REMEDIES has declared, sequenced by announce and record date.
CORONA REMEDIES corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About CORONA REMEDIES: business, sector, key facts.
What CORONA REMEDIES does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
CORONA REMEDIES is a listed Indian equity, listed as NSE: CORONA, BSE: 544644.
CORONA REMEDIES
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B BLACKBIO DX (3BBLACKBIO) Share PricePeer
- ABBOTT INDIA (ABBOTINDIA) Share PricePeer
- ACUTAAS CHEMICALS (ACUTAAS) Share PricePeer
- ANLON HEALTHCARE (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Other overvalued NSE stocksScreener
- Top quality scorecard stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about CORONA REMEDIES (CORONA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of CORONA REMEDIES (CORONA)?
The current share price of CORONA REMEDIES (CORONA) is ₹2,010.00. Today, the stock has gained by ₹6.10 (0.3%), trading in a range of ₹1,985.90 to ₹2,026.00. The stock opened at ₹2,000.10 with a trading volume of 17,444 shares.
02Is CORONA REMEDIES stock a good investment for long-term?
CORONA REMEDIES can be considered for long-term investment based on several factors. The company has a market capitalization of ₹12,312.75 Cr., P/E ratio of 61.87, ROE of 24.28%, and ROCE of 20.94%. The dividend yield stands at 0.5%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of CORONA REMEDIES stock?
The 52-week high price of CORONA REMEDIES (CORONA) is ₹2,292.40, while the 52-week low is ₹1,336.60. Currently trading at ₹2,010.00, the stock is 50.38% above its 52-week low and 12.32% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy CORONA REMEDIES stock at the current price?
Whether to buy CORONA REMEDIES stock at ₹2,010.00 depends on multiple factors. The stock is currently trading with a P/E ratio of 61.87 and P/B ratio of 16.49. Today's performance shows a gain of 0.3%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of CORONA REMEDIES and when is the next dividend?
CORONA REMEDIES offers a dividend yield of 0.5%, which means for every ₹100 invested at the current price of ₹2,010.00, you can expect to receive approximately ₹0.50 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of CORONA REMEDIES?
CORONA REMEDIES's key financial metrics include: P/E Ratio: 61.87, P/B Ratio: 16.49, ROE: 24.28%, ROCE: 20.94%, Dividend Yield: 0.5%, EPS: ₹9.83, Book Value: ₹122.12, and Debt-to-Equity: 0.19. The company's market cap stands at ₹12,312.75 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is CORONA REMEDIES stock performing today in the market?
CORONA REMEDIES stock opened at ₹2,000.10 and is currently trading at ₹2,010.00, showing a gain of ₹6.10 (0.3%). The intraday high is ₹2,026.00 and low is ₹1,985.90. The trading volume stands at 17,444 shares, indicating moderate market participation today.
08What is the P/E ratio of CORONA REMEDIES and what does it indicate?
CORONA REMEDIES has a Price-to-Earnings (P/E) ratio of 61.87, which means investors are willing to pay 61.87 for every ₹1 of earnings. With an EPS of ₹9.83, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about CORONA REMEDIES (CORONA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.